More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Another study found that in late 2021 and 2022, COVID death rates among unvaccinated people were 14 times the rates of those ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

High vaccine wastage and low vaccination and booster rates marred the government’s P74.68-million COVID-19 National ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...